ARTE

TO1

Strengthening research, technological development and innovation

The project in numbers
Duration:
30 months
Start date: 01.10.17
End date: 31.03.20
N. Partner: 6
 
Progress
Budget:
1.285.297,50€
Budget FERS:
1.092.502,87€

The project in numbers

Duration: 
30 months
Start / End: 
01.10.17 to 31.03.20
Project progress: 
33%
Budget: 
1285297.50€
Budget FERS: 
1092502.87€

ARTE

Ecosystem for Advanced Regenerative Medicine Therapies
Priority Axis 1

Promoting innovation capacities for a more competitive area

Specific Objective: 
OS 1.1.
Investment Priority: 
PI 1b
Typology: 
Standard
Overall Objective of the Project: 

The overall goal of the Arte project is to improve cross-border cooperation among hospitals, Research Centres, Universities, SMEs, and Technology Parks, in order to promote the transfer of innovative biomedical techniques for greater competitiveness in the field of regenerative medicine throughout the cross-border area.

Project summary: 

The ARTE project’s challenge is to transform the program area into a reference point for the European ecosystem for innovative therapies and regenerative medicine (which, with a global market of € 20 billion and a CAGR growth of 36%, is a priority of the EU Commission), by rendering this innovative territory attractive for investments in smart health, as one of the key S3 sectors. The general goal is to improve the area’s competitiveness by increasing cross-border cooperation among Italian and Slovenian subjects: the Research Centres, Hospitals, SMEs, Technology Parks, and Private Investors that currently aren’t connected don’t collaborate with one another. The expected change will entail the start of collaboration, the sharing of know-how, and the transfer of technology for the development of innovative treatments, including a pilot cell therapy project for Osteoarthritis (a disabling disease affecting over 10% of the adult population in the program area, and 50% of people over 60). The main results jointly achieved include the collaboration among 3 research centres/hospitals, 2 partner companies, and 2 Networks of biomedical companies with over 70 SMEs, and the development of 5 innovative products/services: imaging and cell separation systems, cellular expansion monitoring software, fluidic and micro-fluidic systems, and FAD training modules for professionals, patients, and the biomedical market as a whole. The cross-border approach is necessary to guarantee the complementarity of the subjects operating within the biomedical sector with specific expertise in the program area. The project is highly innovative, as it introduces new personalised and regenerative medicine methodologies with enormous market potential (e.g. the use of stem cells for the regeneration of tissues, instead of surgical intervention), which will lead to improved quality of life for patients thanks to innovative, safe, and effective therapies.

Main results: 

The result of the project is increased cooperation among the hospitals, Research Centres, Universities, SMEs, and Technology Parks operating in the biomedical sector through the creation of a cross-border public/private Network aimed at developing and promoting a new innovative treatment in the biomedical field, with the joint development of innovative products and services in regenerative medicine.

Partner

Lead Partner

Tehnološki park Ljubljana d.o.o.

Osrednjeslovenska
SLO

Project partner 1

Ortopedska bolnišnica Valdoltra

Obalno-kraška
SLO

Project partner 2

Univerza v Ljubljani (Fakulteta za farmacijo)

Osrednjeslovenska
SLO

Project partner 3

VIVABIOCELL SPA

Udine
ITA

Project partner 4

Azienda Sanitaria Universitaria Integrata di Udine

Udine
ITA

Project partner 5

Biovalley Investments S.p.A.

Trieste
ITA

Documents

Poster evento annuale 30/05/2018Poster evento annuale 30/05/2018
ARTE_ITA_1.pdf
( 459 bytes, published on 7 June, 2018 - 12:49 )

Objectives and Activities

OBIETTIVI PRINCIPALI DEL PROGETTO

L'obiettivo complessivo di ARTE è di favorire gli investimenti, l’innovazione imprenditoriale e la competitività, migliorando la cooperazione tra strutture ospedaliere, Centri di Ricerca, Università, PMI e Parchi Tecnologici in tema di Medicina Rigenerativa. Il focus è sulle nuove terapie per l’osteoartrosi e su dispositivi biomedicali e servizi che consentano di ridurre i costi. Verrà creato un Network pubblico-privato che favorirà la nascita di un ecosistema collegato ad iniziative europee e ad investitori internazionali.

SITUAZIONE ATTUALE DELL’IMPLEMENTAZIONE PROGETTUALE (30/05/2018)

Nel primo periodo si sono raggiunti importanti risultati. L'Ospedale ortopedico Valdoltra ha già presentato la documentazione professionale di uno studio clinico alla Commissione per l'etica medica della Repubblica di Slovenia, che ha emesso il suo consenso il 22 febbraio 2018. Sono iniziate le attività di organizzazione dei bandi per la selezione di PMI fornitrici di servizi e prodotti e per coinvolgere PP ed investitori EU e internazionali.

Contacts

Tehnološki park Ljubljana d.o.o.

00386 (0) 16203406
Tehnološki park 19, 1000 Ljubljana, Slovenija
Simona Knežević Vernon

Ortopedska bolnišnica Valdoltra

00386 (0) 56696100
Jadranska cesta 31, 6280 Ankaran/Ancarano, Slovenija
Ingrid Milošev

Univerza v Ljubljani (Fakulteta za farmacijo)

00386 (0) 12418532
Kongresni trg 12, 1000 Ljubljana, Slovenija
Tilen Kranjc

VIVABIOCELL SPA

0039 0432545674
Via del Cotonificio 127, 33100 Udine, Italia
Antonio Sfiligoj

Azienda Sanitaria Universitaria Integrata di Udine

0039 04325543754278
Via Pozzuolo 330, 33100 Udine, Italia
Samantha Gomboso

Biovalley Investments S.p.A.

0039 0408992219
Via Flavia 23/1 34148 Trieste TS, Italia
Bravar Diego